Nizar M. Tannir

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 45 papers. Top paper: “Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial”.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

ESMO Open(2020)10.1136/esmoopen-2020-001079

N/A

6.4DataRank · unranked

524 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +15 more

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000891

N/A

5.8DataRank · unranked

225 citations

Bernard Escudier, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Thomas Powles +24 more

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Cancer(2022)10.1002/cncr.34180

N/A

5.5DataRank · unranked

265 citations

David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2022-005445

N/A

2.7DataRank · unranked

69 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Saby George +9 more

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

European Urology(2021)10.1016/j.eururo.2021.10.001

N/A

2.6DataRank · unranked

80 citations

Nizar M. Tannir, Mauricio Burotto, David F. McDermott, Elizabeth R. Plimack, Philippe Barthélémy +17 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009495

N/A

0.615DataRank · unranked

19 citations

Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir +13 more

Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa064

N/A

0.557DataRank · unranked

40 citations

Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch +15 more

A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer

European Journal of Cancer(2020)10.1016/j.ejca.2019.12.027

N/A

0.435DataRank · unranked

7 citations

Nicholas Spetsieris, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana M. Aparicio +14 more

A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer(2020)10.1016/j.clgc.2020.05.013

N/A

0.425DataRank · unranked

16 citations

Myrto Boukovala, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana M. Aparicio +15 more

Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial

Nature Communications(2025)10.1038/s41467-024-55642-8

N/A

0.406DataRank · unranked

12 citations

Herbert Yu, Ying Yuan, Jianfeng Chen, Xinmiao Yan, Menuka Karki +22 more

Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes

Molecular Cancer Research(2020)10.1158/1541-7786.mcr-20-0751

N/A

0.373DataRank · unranked

11 citations

Andrew W. Hahn, Pavlos Msaouel, Alexander Andreev-Drakhlin, Funda Meric‐Bernstam, Aung Naing +17 more

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

npj Precision Oncology(2023)10.1038/s41698-023-00369-w

N/A

0.312DataRank · unranked

7 citations

Roman Groisberg, Ralph Zinner, Andrew W. Hahn, Aung Naing, Shizhen Zhang +16 more

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma

Cancer Medicine(2025)10.1002/cam4.70280

N/A

0.212DataRank · unranked

3 citations

Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bülent Yılmaz, Bettzy Stephen +16 more

Renal Cell Carcinoma of Variant Histology

Hematology/Oncology Clinics of North America(2023)10.1016/j.hoc.2023.04.019

N/A

0DataRank · unranked

48 citations

Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel

Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma

Cancer Cell(2020)10.1016/j.ccell.2020.04.002

N/A

0DataRank · unranked

143 citations

Gabriel G. Malouf, Xiaoping Su, Hui Yao, Durga Nand Tripathi, Melinda Soeung +35 more

Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03383-w

N/A

0DataRank · unranked

4 citations

Amy K. Erbe, Jennifer Birstler, KyungMann Kim, Ute Hoch, Sue Currie +8 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of Oncology(2024)10.1016/j.annonc.2024.07.727

N/A

0DataRank · unranked

198 citations

Laurence Albigès, David F. McDermott, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers +20 more

Clinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients

European Urology Oncology(2024)10.1016/j.euo.2024.07.002

N/A

0DataRank · unranked

22 citations

Panayiotis Kontoyiannis, Andrew W. Hahn, Zita Dubauskas Lim, Priya Rao, Jessica P Cheng +8 more

Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study

Clinical Genitourinary Cancer(2024)10.1016/j.clgc.2024.102065

N/A

0DataRank · unranked

6 citations

Pavlos Msaouel, Priya Rao, José A. Karam, Nizar M. Tannir, Chad Tang +1 more

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.10.022

N/A

0DataRank · unranked

5 citations

Salvatore La Rosa, Tian Zhang, Phillip M. Pierorazio, Laurence Albigès, Kathryn E. Beckermann +19 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity

Immunity(2025)10.1016/j.immuni.2025.04.020

N/A

0DataRank · unranked

18 citations

Benxia Hu, Yalan Deng, Melinda Soeung, Jun Yao, Lanxin Bei +27 more

Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial

Nature Communications(2025)10.1038/s41467-025-57009-z

N/A

0DataRank · unranked

14 citations

Jianjun Gao, Sreyashi Basu, Daniel D. Shapiro, José A. Karam, Rebecca S. Tidwell +22 more

CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3324

N/A

0DataRank · unranked

7 citations

Menuka Karki, Kyle A. Blum, Jean‐Philippe Bertocchio, Rong He, Durga Nand Tripathi +17 more

Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase–Deficient Renal Cell Carcinoma

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0703

N/A

0DataRank · unranked

5 citations

Manuel Ozambela, Menuka Karki, Rong He, Pankaj Kumar Chauhan, Pedro I. Pesquera +17 more

Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102423

N/A

0DataRank · unranked

3 citations

Nizar M. Tannir, Funda Meric-Bernstam, Jennifer King, Martin H. Voss, Jessica P Cheng +27 more

SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1003

N/A

0DataRank · unranked

17 citations

Yanting Zhang, Daniel J. McGrail, X. Zhang, Truong Lam, Anh Hoang +11 more

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Cancer(2020)10.1002/cncr.33033

N/A

0DataRank · unranked

340 citations

Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi +26 more

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy

Cancer(2020)10.1002/cncr.32991

N/A

0DataRank · unranked

44 citations

Eric Umbreit, Levi C. Holland, Cindy Gu, Nizar M. Tannir, Surena F. Matin +4 more

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values

Cancer Treatment and Research Communications(2020)10.1016/j.ctarc.2020.100166

N/A

0DataRank · unranked

32 citations

Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel, Jacob J. Adashek

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2283

N/A

0DataRank · unranked

57 citations

Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer +16 more

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies

The Oncologist(2021)10.1002/onco.13770

N/A

0DataRank · unranked

37 citations

Tharakeswara Bathala, Andrew W. Hahn, Lianchun Xiao, Munevver Duran, Jeremy A. Ross +6 more

Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.08.007

N/A

0DataRank · unranked

36 citations

Andrew James Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Pheroze Tamboli +7 more

Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation

British Journal of Urology(2021)10.1111/bju.15541

N/A

0DataRank · unranked

33 citations

Aradhana M. Venkatesan, Pavlos Msaouel, Amol J. Ghia, Jing Li, D.N. Yeboa +13 more

Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival

Urologic Oncology Seminars and Original Investigations(2021)10.1016/j.urolonc.2021.08.022

N/A

0DataRank · unranked

9 citations

Daniel D. Shapiro, Mary E. Westerman, Hyunsoo Hwang, Xuemei Wang, Luis Segarra +7 more

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies

OncoTargets and Therapy(2021)10.2147/ott.s291801

N/A

0DataRank · unranked

3 citations

Ecaterina E. Dumbrava, Binoj C. Nair, Wendy Xiong, Xu Li, Rosa Mostorino +12 more

Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials

Clinical Genitourinary Cancer(2021)10.1016/j.clgc.2021.07.004

N/A

0DataRank · unranked

2 citations

Andrew W. Hahn, Pavlos Msaouel, Funda Meric‐Bernstam, Nathaniel R. Wilson, Aung Naing +18 more

High-intensity exercise is a risk factor for renal medullary carcinoma in individuals with sickle cell trait

medRxiv(2021)10.1101/2021.02.23.21252313

N/A

0DataRank · unranked

0 citations

Melinda Soeung, Luigi Perelli, Eleonora Dondossola, Devaki Shilpa Surasi, Durga Nand Tripathi +20 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Nature Communications(2023)10.1038/s41467-023-38342-7

N/A

0DataRank · unranked

49 citations

Pavlos Msaouel, Cara Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita +17 more